Home Newsfeeds Keybanc Initiates Coverage On Stryker with Sector Weight Rating

Keybanc Initiates Coverage On Stryker with Sector Weight Rating

Keybanc analyst Matthew Mishan initiates coverage on Stryker (NYSE:SYK) with a Sector Weight rating.

byBenzinga Newsdesk

January 25, 2023

1 minute read

Keybanc analyst Matthew Mishan initiates coverage on Stryker (NYSE:SYK) with a Sector Weight rating.

JonesTrading Initiates Coverage On BrightSpire Capital with Buy Rating, Announces Price Target of $11

By Benzinga Newsdesk

December 6, 5:32 AM

JonesTrading analyst Jason Stewart initiates coverage on BrightSpire Capital (NYSE:BRSP) with a Buy rating and announces Price Target of $11.

BRSP

PolyPid Announces Peer-Reviewed Publication Of Phase 2 Clinical Trial Results For D-PLEX₁₀₀ In The Prevention Of Surgical Site Infections In Abdominal Surgery

By Benzinga Newsdesk

September 19, 7:16 AM

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the peer-reviewed publication of positive clinical

PYPD

PhenixFIN Reports FY23 NAV Per Share Grew 23%, From $57.29 Per Share To $70.75 Per Share; Q4 Total Investment Income Of $5.7M

By Benzinga Newsdesk

December 22, 5:03 PM

PhenixFIN Corporation (NASDAQ:PFX, PFXNZ)))) (the "Company"), a publicly traded business development company, today announced its financial results for the fiscal fourth quarter of 2023. Highlights

PFX

Wingstop Adopts Inaugural $250M Share Repurchase Program

By Shivani Kumaresan

August 17, 10:27 AM

Wingstop Inc (NASDAQ: WING) said its board of directors approved a new share repurchase program for up to $250.0 million of shares, effective immediately.

WING

Keybanc Initiates Coverage On Stryker with Sector Weight Rating

Related Posts

JonesTrading Initiates Coverage On BrightSpire Capital with Buy Rating, Announces Price Target of $11

PolyPid Announces Peer-Reviewed Publication Of Phase 2 Clinical Trial Results For D-PLEX₁₀₀ In The Prevention Of Surgical Site Infections In Abdominal Surgery

PhenixFIN Reports FY23 NAV Per Share Grew 23%, From $57.29 Per Share To $70.75 Per Share; Q4 Total Investment Income Of $5.7M

Wingstop Adopts Inaugural $250M Share Repurchase Program